Should I buy Vertex Pharmaceuticals (VRTX) stock or is it too late?
⭐ The most reliable of them, either direction: UBS — 66% of its targets hit on this sector (358 calls tested). It aims for $615 (+27 %), call made on September 29, 2026, maturing on September 29, 2027 (15 d ago).
Firm-by-firm track record on Vertex Pharmaceuticals
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Baird | 100 % | +33.8 % | 8 | $350 -28% |
| Jefferies | 67 % | +31.5 % | 6 | $580 +20% |
| Evercore ISI Group | 100 % | +30.1 % | 11 | $530 +9% |
| Wells Fargo | 89 % | +24.2 % | 9 | $515 +6% |
| Bernstein | 80 % | +23.7 % | 5 | $572 +18% |
| TD Cowen | 80 % | +20.4 % | 5 | $550 +13% |
| UBS | 74 % | +18.4 % | 19 | $615 +27% |
| RBC Capital | 73 % | +17.3 % | 15 | $576 +19% |
✅ Reasons to believe
- 80% of analysts rate it a buy (Buy consensus, 10 ratings) — a sign of market conviction.
- Median price target $574, i.e. +18% from the current price ($485).
⚠️ Reasons to hesitate
- Even the most reliable firm on VRTX, Baird (100% hit rate, 8 scored calls), only targets $350 (call made on July 7, 2026, maturing on July 7, 2027) (-28%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 10 ratings, 1 is neutral and 1 is a sell.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on VRTX
Median target $574 (+18%) · 10 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Vertex Pharmaceuticals now?
We won't decide for you. The facts: 80% of analysts rate it a buy, median target $574 (+18%), and Baird (most reliable on VRTX, 100%) targets $350. Weigh that against valuation (P/E ~28). This is not personalized advice.
Is it too late to invest in Vertex Pharmaceuticals?
Not according to analysts: the median target ($574) is still +18% above the current price ($485) (most reliable on VRTX: Baird, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Vertex Pharmaceuticals still worth investing in?
It depends on the gap between the price ($485) and its estimated value: analysts target $574 on median (+18%), with 80% buys (most reliable on VRTX: Baird, 100%). Cross-check with their real reliability on VRTX and the cautions above. Information, not advice.
What's the main risk in buying VRTX?
Even the most reliable firm on VRTX, Baird (100% hit rate, 8 scored calls), only targets $350 (call made on July 7, 2026, maturing on July 7, 2027) (-28%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Vertex Pharmaceuticals profile (consensus, analyst reliability, price target, performance).